

separated by chromatography on silica gel using hexane-ethyl acetate. Hydrolysis of 20a afforded 21a as a colorless solid which was recrystallized from acetone-hexane to give needles, mp 206–208°.

The ir spectrum shows absorption at 3600, 1734, and 1713 cm⁻¹. The NMR spectrum shows three-proton singlets at δ 0.90 and 1.25 and a broad one-proton signal at δ 3.70. Anal. (C₁₉H₂₈O₃) C, H.

4 α ,6-Cyclo-5 β -androsterane-3,17-dione (22). The tosylate 21b was prepared in the usual manner as a white foam. To a solution of 21b (1.40 g, 3.16 mmol) in 100 ml of *tert*-butyl alcohol was added 3.2 ml of a 1.0 M solution of potassium *tert*-butoxide. The solution was stirred for 30 min and worked up in the usual manner to give 0.90 g of a pale yellow solid. Two recrystallizations from ethanol afforded 0.65 g (72%) of colorless crystals, mp 195–197°.

The ir spectrum shows carbonyl absorption at 1730 and 1679 cm⁻¹. The NMR spectrum has three-proton singlets at δ 0.85 and 1.21. Anal. (C₁₉H₂₆O₂) C, H.

Acknowledgment. This research was supported by Contract NICHD-2719 from the Contraceptive Development Branch, Center for Population Research, National Institutes of Health. We acknowledge many useful discussions with Dr. Marvin Karten of that office. The NMR facility used was supported by National Institutes of Health Research Grant No. R00708 from the Division of Research Resources.

References and Notes

- (1) (a) D. Lednicer, Ed., "Contraception", Marcel Dekker, New York, N.Y., 1969; (b) "Pharmacology of the Endocrine System and Related Drugs. Progesterone, Progestational Drugs and Antifertility Agents", Vol. I and II, Pergamon Press, Elmsford, N.Y., 1972; (c) V. Petrow, *Chem. Rev.*, **70**, 713 (1970); (d) R. Wiechert, *Angew. Chem., Int. Ed. Engl.*, **9**, 321 (1970); (e) P. D. Klimstra, *Am. J. Pharm. Educ.*, **34**, 630 (1970).
- (2) Reference 1a, p 18; G. Hecht-Lucari, G. Baldratti, and G. Sala, *Endocrinology*, **68**, 543 (1961); W. G. Wiest, *ibid.*, **87**, 43 (1970). It is possible that 5 α -reduced derivatives may play a role in the mechanism of action, but the evidence is less clear than with androgenic compounds.
- (3) (a) M. Charton in "The Chemistry of Alkenes", Vol. 2, S. Patai, Ed., Interscience, New York, N.Y., 1970, p 511; (b) J. W. Lauher and J. A. Ibers, *J. Am. Chem. Soc.*, **97**, 561 (1975); (c) R. S. Brown and T. G. Traylor, *ibid.*, **95**, 8025 (1973); (d) S. R. Tanny and F. W. Fowler, *ibid.*, **95**, 7320 (1973); (e) M. Yu. Lukina, *Russ. Chem. Rev.*, **31**, 419 (1962); (f) P. F. Torrence and B. Witkop, *Biochemistry*, **11**, 1737 (1972).
- (4) K. Fotherby, *Adv. Biosci.*, **3**, 43 (1968).
- (5) M. D. Morgan and J. D. Wilson, *J. Biol. Chem.*, **245**, 3781

- (1970).
- (6) (a) R. Wiechert and F. Newmann, *Arzneim.-Forsch.*, **15**, 244 (1965); (b) J. Martinez-Manowton, J. Giner-Velasquez, and H. Rudel, *Fertil. Steril.*, **18**, 57 (1967); (c) S. J. Halkes, J. Hartog, L. Morsink, and A. M. de Wachter, *J. Med. Chem.*, **15**, 1288 (1972); (d) J. W. Dean, G. O. Potts, and R. G. Christiansen, *ibid.*, **10**, 795 (1967); (e) L. J. Chinn and B. N. Desai, *ibid.*, **18**, 268 (1975); (f) G. Tarzia, N. H. Dyson, I. T. Harrison, J. A. Edwards, and J. H. Fried, *Steroids*, **9**, 387 (1967).
- (7) For other examples, see J. R. Williams and H. Ziffer, *Chem. Commun.*, 469 (1967); H. Dutler et al., *Helv. Chim. Acta*, **45**, 2346 (1962); J. F. Kerwin et al., *J. Org. Chem.*, **27**, 3628 (1962).
- (8) For a recent discussion of this topic and leading references, see R. J. B. King and W. I. P. Mainwaring, "Steroid-Cell Interactions", Butterworths, London, 1974.
- (9) Reference 1c, p 717.
- (10) J. B. Brown and H. A. F. Blair, *Proc. R. Soc. Med.*, **53**, 433 (1960).
- (11) W. von E. Doering, E. J. Fossel, and R. L. Kayne, *Tetrahedron*, **21**, 25 (1965); H. Meier and K. Zeller, *Angew. Chem., Int. Ed. Engl.*, **14**, 32 (1975).
- (12) J. T. Edward, D. Holder, W. H. Lunn, and I. Puskas, *Can. J. Chem.*, **39**, 599 (1961).
- (13) J. T. Edward, D. L'Anglais, and S. Meyerson, *Can. J. Chem.*, **44**, 1866 (1966).
- (14) L. Friedman and H. Schechter, *J. Am. Chem. Soc.*, **81**, 5513 (1959).
- (15) W. G. Dauben and G. H. Berezin, *J. Am. Chem. Soc.*, **89**, 3449 (1967).
- (16) W. G. Dauben and E. J. Deviny, *J. Org. Chem.*, **31**, 3794 (1966).
- (17) Review: J. M. Conia, *Angew. Chem., Int. Ed. Engl.*, **7**, 570 (1968).
- (18) D. N. Kirk and M. P. Hartshorn, "Steroid Reaction Mechanisms", Elsevier, Amsterdam, 1968, p 161.
- (19) M. Nussim, Y. Mazur, and F. Sondheimer, *J. Org. Chem.*, **29**, 1120 (1964).
- (20) E. Lederer, F. Marx, D. Mercier, and G. Perot, *Helv. Chim. Acta*, **29**, 1354 (1946).
- (21) W. S. Allen, S. Bernstein, and R. Littell, *J. Am. Chem. Soc.*, **76**, 6116 (1954).
- (22) Using Zurcher values; cf. N. S. Bhacca and D. H. Williams, "Applications of NMR Spectroscopy in Organic Chemistry", Holden-Day, San Francisco, Calif., 1964, p 13.
- (23) R. Gardi, C. Pedrali, and A. Ercoli, *Gazz. Chim. Ital.*, **93**, 525 (1963).
- (24) J. Hill, I. Irrate, K. Schaffner, and O. Jeger, *Helv. Chim. Acta*, **49**, 292 (1966).
- (25) J. A. Vida, "Androgens and Anabolic Agents", Academic Press, New York, N.Y., 1969, p 31.

Synthesis and Pharmacology of 2,9 α -Dimethyl-2'-hydroxy-6,7-benzomorphan

Hirozumi Inoue¹ and Everette L. May*


Laboratory of Chemistry, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, Bethesda, Maryland 20014. Received July 14, 1975

2,9 α -Dimethyl-2'-hydroxy-6,7-benzomorphan (14) has been synthesized in six to seven steps from *trans*-3,4-dihydro-4-(2-dimethylaminoethyl)-6-methoxy-3-methyl-1(2*H*)-naphthalenone (1). The key reaction of the sequence was mercuric acetate cyclization of *trans*-1,2-dihydro-1-(2-methylaminoethyl)-7-methoxy-2-methylnaphthalene (8) which gave a mixture of 9 α -methyl-8 α -hydroxy-6,7-benzomorphan (9, 49%), the corresponding acetate (10, 13%), and the 9 β -methyl-8 α -hydroxy-6,7-benzomorphan (11, 5%). In the presence of Et₃N, the yields were 16, 37, and 0%, respectively. Structural assignments are based on ir, NMR, and mass spectral data and on chemical conversions.

Recently,² we reported that cyclization of 2,3-*trans*-3,4-*cis*-2-bromo-3,4-dihydro-4-(2-dimethylaminoethyl)-6-methoxy-3-methyl-1(2*H*)-naphthalenone gave 2,9 β -dimethyl-2'-methoxy-8-oxo-6,7-benzomorphan metho-

bromide from which 2,9 β -dimethyl-2'-hydroxy-6,7-benzomorphan was obtained. The corresponding 2,3-*cis*-3,4-*trans* isomer gave, instead of the expected 9 α -methylbenzomorphan methobromide, 4-(2-dimethyl-


Scheme I



aminoethyl)-6-methoxy-3-methyl-1-naphthol.² The synthesis of 2,9 α -dimethyl-2'-hydroxy-6,7-benzomorphan (14)³ by an alternate route starting from *trans*-3,4-dihydro-4-(2-dimethylaminoethyl)-6-methoxy-3-methyl-1(2*H*)-naphthalenone (1)² has now been achieved.

Chemistry. The key intermediate, *trans*-1,2-dihydro-1-(2-methylaminoethyl)-7-methoxy-2-methylnaphthalene (8), was best prepared (overall yield 41%) by treatment of 1 with ClCO₂Et, hydrolysis of the resultant urethane (2) to 4 with 12 *M* HCl, reduction of 4 to 6 (LiAlH₄), and dehydration of 6 with ClCO₂Et in CH₂Cl₂. Compound 8 was obtained from 1 in 19% overall yield in a slightly altered sequence as shown at the left of Scheme I (1 → 3 → 5 → 7 → 8). The low-yield step in this case was in the hydrolysis (KOH-*n*-BuOH) of urethane 7. When 12 *M* HCl was used instead of KOH, polymerization took place.

Treatment of 8 with Hg(OAc)₂ in THF-H₂O⁴ gave the 9 α -methyl-8 α -hydroxy-6,7-benzomorphan 9 (49%), the corresponding acetate 10 (13%), and the 9 β -methyl-8 α -hydroxy isomer 11 (5%). When Et₃N was used in the cyclization medium, the yields of 9 and 10 were 16 and 39%, respectively, and no 11 was detected. Evidently, inversion (by allylic rearrangement)⁵ at C-2 of 8 to give the 5% of 11 isolated in the first instance is inhibited by base. Compounds 9 and 10 were interconvertible.



Treatment of 9 with 50% HI-AcOH and red P (reflux) gave 36% of desired benzomorphan 14, which was better prepared (70% overall yield) by reduction of 9 (H₂, Pd,

HClO₄, AcOH) to 12 and subsequent hydrolysis (refluxing 48% HBr). Compound 11 was converted to the known 2,9 β -dimethyl-2'-methoxy-6,7-benzomorphan 13 (Pd/C, HClO₄, AcOH).

The mass spectra of 9 and 11 were similar to the spectrum of 2,9 β -dimethyl-8 β -hydroxy-2'-methoxy-6,7-benzomorphan (15).² However, in 9, 12, and 14, the ratios of the relative intensities of *m/e* 84 to 110 were higher than those for 11 and 15 and corresponding 9 β isomers in accordance with the findings of Vaughan and Beckett.⁶

NMR spectra served to establish the 8-OH of 9 and 11 and 9-CH₃ of 9, 10, 12, and 14 as α .³ Thus 9 and 11 showed singlets⁷ at 4.98 and 4.87, respectively, for the C-8 H as opposed to a doublet for 15, δ 5.18 ($J = 6$ Hz).² Methyl signals for C-9 appeared at δ 1.09 (CD₃OD-D₂O), 0.96 (CDCl₃), 0.97 (CD₃OD), and 0.89 (CD₃OD) for 9, 10, 12, and 14, respectively, and at 1.33 (CDCl₃) and 1.45 (D₂O) for 11 and 2,9 β -dimethyl-2'-hydroxy-6,7-benzomorphan,² respectively.^{2,8,9} These mass and NMR spectral data leave little doubt about stereochemistry at C-8 and C-9.

Pharmacology. In the hot-plate test for analgesia,¹⁰ the α -isomer 14 has an ED₅₀ of 4.3 (3.1-5.9) mg/kg (white, male mice, sc administration) compared with 1.1 for the β isomer² (in general, β isomers are 10-30 times more potent than corresponding α compounds).¹¹ In the same test the ED₅₀ for morphine is 1.2 and that of pethidine is 4.5.¹⁰ Like the β compound,² 14 is not morphine-like in morphine-dependent monkeys. It precipitates an abstinence syndrome of long duration which is characterized almost entirely by abdominal cramps and irritability on handling without the signs of hyperexcitability or movement within the monkey cage which are normally seen in precipitated abstinence. The 9 β analog² and the

9-demethyl homolog¹² also have antagonistic properties.

Thus it is apparent that when carbon 5 is unsubstituted (tertiary) analgesic activity is somewhat but not markedly lower than when it contains an alkyl substituent.^{11,12} Also, in the three test cases to date, these C-5 nor compounds have mixed agonist-antagonist properties in contrast to *rac*-5-alkyl- and 5,9-dialkyl-6,7-benzomorphans.¹¹

Finally, only when the 9-substituent is in β orientation is there a pronounced enhancement of analgesic potency whether C-5 is tertiary¹² or quaternary.¹¹ It is well known^{8,9,13} that a 9 β -alkyl substituent hinders reaction of the free electron pair of nitrogen with CH₃⁺ but probably not with H⁺. Therefore, it is presumed that the "receptor effect" of a 9-alkyl substituent is topological rather than steric (for nitrogen) or electronic.

Experimental Section

Melting points (Hershberg) are corrected. Ir, NMR, and mass spectra were obtained on a Perkin-Elmer 257, Varian Model A-60A (unless otherwise noted), and a Hitachi RMU-6E (70 eV), respectively. Analytical results are indicated only by symbols of the elements and are within 0.4% of theory.

trans-3,4-Dihydro-6-methoxy-3-methyl-4-(2-methyl-aminoethyl)-1(2H)-naphthalene (4) Oxalate. ClCO₂Et (3.6 g, 33.2 mmol) was added to 6.4 g (24.6 mmol) of 1 in 200 ml of C₆H₆ (reflux). After refluxing for 2 hr, the cooled solution was washed with dilute HCl and H₂O, then dried (MgSO₄), and evaporated to dryness to give 7.3 g (90%) of oily 2; from the HCl layer, 360 mg of 1 was recovered.

The crude 2 (7.3 g, 22.9 mmol) and 300 ml of 12 M HCl were kept under reflux for 16.5 hr. After evaporation of the solution to dryness in vacuo, the residue was dissolved in H₂O, made basic with K₂CO₃, and extracted with Et₂O. The extracts were dried (MgSO₄) and evaporated to give 3.7 g (66%) of 4: ν (liquid) 1675 cm⁻¹. The oxalate (from EtOH) melted at 180–181°. Anal. (C₁₇H₂₃NO₆) C, H, N.

trans-1,2-Dihydro-2-methyl-7-methoxy-1-(2-dimethyl-aminoethyl)naphthalene (5) Oxalate. To 1.53 g (5.85 mmol) of 1 (base) in 40 ml of dry Et₂O was added 300 mg (7.9 mmol) of LiAlH₄. The mixture was stirred at room temperature for 2 hr, treated with 20 ml of H₂O (ice cooling), and filtered. The filtrate was washed with H₂O, dried, and evaporated to give 1.43 g (93%) of an oil (3): ν (liquid) 3450 cm⁻¹.

A mixture of 527 mg (2.0 mmol) of 3, 20 ml of C₆H₆, and 440 mg (4.1 mmol) of ClCO₂Et was stirred at room temperature for 18 hr and evaporated to dryness in vacuo. The residual oil (547 mg) in H₂O was made basic with 12 M NH₄OH and extracted with Et₂O to give, after drying and evaporation of the Et₂O, 450 mg (92%) of oily 5: mass spectrum M⁺ 245, 73 (base, CH₃CH₂N⁺HMe). The oxalate (from Me₂CO–Et₂O) melted at 121–122°. Anal. (C₁₆H₂₃NO₂·C₂H₄O₂) C, H, N.

trans-1,2-Dihydro-7-methoxy-2-methyl-1-(2-methyl-aminoethyl)naphthalene (8) Oxalate. A. From 4. To 3.7 g (15.0 mmol) of 4 (base) in 300 ml of dry Et₂O was added 1.5 g (0.0395 mol) of LiAlH₄ at room temperature. The mixture was refluxed for 30 min and treated (ice cooling) with H₂O. The mixture was filtered and the precipitate was washed with THF. Drying and evaporation of the Et₂O–THF filtrate gave 3.5 g (86%) of oily 6 which was converted to 3.7 g (13 mmol) of gummy hydrochloride. To this in 100 ml of CH₂Cl₂ was added 2.1 g (19.4 mmol) of ClCO₂Et. The mixture was stirred at room temperature for 2 days and evaporated to dryness in vacuo. The residue, in H₂O, was made alkaline with 12 M NH₄OH and extracted with Et₂O. The extracts, after drying and evaporation, gave 2.7 g of 8 which was converted to 3.3 g (80%) of oxalate: mp 168–170° (from EtOH); ir (liquid base) 3320, 1640 cm⁻¹; NMR (oxalate, CD₃OD) δ 0.92 (d, J = 7 Hz, 3, C-2 CH₃), 2.63 (s, 3, NCH₃), ca. 5.9 (m, 1, C-3, H), 6.4 (d, J = 10 Hz, 1, C-4 H); mass spectrum 231 (M⁺), 44 (base, CH₃N⁺H=CH₂). Anal. (C₁₅H₂₁NO₂·C₂H₄O₂) C, H, N.

B. From 5. To 387 mg (1.58 mmol) of 5 in 20 ml of refluxing C₆H₆ was added 220 mg (2.03 mmol) of ClCO₂Et. Refluxing was continued for 4 hr. After cooling, H₂O and Et₂O were added. The organic layer was dried and evaporated to give 330 mg of oily 7: ν 1700 cm⁻¹; mass spectrum 303 (M⁺), 116 [base, CH₂=N⁺·

(CH₃)CO₂Et]. The aqueous layer, after treatment with NH₄OH, gave 120 mg of 5.

A mixture of 140 mg (0.461 mmol) of 7, 120 mg (2.1 mmol) of KOH, and 3 ml of *n*-BuOH was refluxed for 40 hr (N₂ atmosphere), evaporated in vacuo, treated with 2 ml of H₂O, and extracted with Et₂O. The Et₂O was shaken with dilute HCl. The HCl extracts were basified with 12 M NH₄OH and extracted with Et₂O. Drying and evaporation of the extracts gave 55 mg of oily 8 which was converted to 50 mg of 8 oxalate (34%) (GLC pure), mp 167–168°.

Cyclization of 5. A. In THF–H₂O. To 1.6 g (6.93 mmol) of 8 (GLC pure), 75 ml of THF, and 38 ml of H₂O was added 2.6 g (8.2 mmol) of Hg(OAc)₂, and the mixture was stirred at room temperature for 27–45 hr. To this stirred mixture (ice cooling) was added 40 ml of 10% KOH and 1 g (26 mmol) of NaBH₄. After 1 hr and Et₂O extraction, 1.6 g of colorless oil was obtained from the dried Et₂O extracts. It was chromatographed on 80 g of SiO₂.

Elution with CHCl₃–MeOH (98:2) gave 350 mg (13%) of 8 α -acetoxy-2,9 α -dimethyl-2'-methoxy-6,7-benzomorphan (10) which, recrystallized from ligroine (bp 30–60°), had mp 94–95°; ir (CHCl₃) 1730, 1650 cm⁻¹; mass spectrum 289 (M⁺), 228 (base); NMR (CDCl₃, 100 MHz) δ 6.01 (s, 1, C-8 H). Anal. (C₁₇H₂₃NO₃) C, H, N.

Elution with CHCl₃–MeOH (96:4) gave 155 mg of 2,9 β -dimethyl-8 α -hydroxy-2'-methoxy-6,7-benzomorphan (11) which was converted to the oxalate (110 mg, 4.8%), mp 179–180°, after a recrystallization from EtOH: ir (liquid, free base) 3400 (broad), 1620, 1580 cm⁻¹; mass spectrum 247 (M⁺, base). Anal. (C₁₅H₂₁NO₂·C₂H₄O₂) C, H, N.

Elution with CHCl₃–MeOH (9:1) gave 960 mg of 2,9 α -dimethyl-8 α -hydroxy-2'-methoxy-6,7-benzomorphan (9) which was converted to 960 mg (49%) of the HCl salt: mp 227–228° dec (from EtOH–Et₂O); ir (CHCl₃, free base) 3300 (broad), 1615, 1585 cm⁻¹; mass spectrum 247 (M⁺), 84 (base). Anal. (C₁₅H₂₁NO₂·HCl·0.5H₂O) C, H, N.

B. In THF–H₂O–Et₃N. Similar reaction of 8 (216 mg, 0.935 mmol) with 388 mg (1.22 mmol) of Hg(OAc)₂, 120 mg (1.19 mmol) of Et₃N, and 10 ml of THF for 45 hr followed by reduction with 100 mg (2.64 mmol) of NaBH₄ and 5 ml of 10% KOH gave 10 (37%) and 9 (16%) but no 11. When HgCl₂ was used, two dimeric compounds of unknown structure were obtained.

2,9 α -Dimethyl-2'-methoxy-6,7-benzomorphan (12) Hydrochloride. Hydrogenolysis of 9 (350 mg, 1.23 mmol) was effected with 160 mg of 10% Pd/C, 60 ml of AcOH, and 3 ml of 60% HClO₄ (H₂ 55 psi, 40°) during 4 days. Filtration and evaporation of the AcOH in vacuo gave a residue which was dissolved in H₂O and treated with 12 M NH₄OH and Et₂O. Drying and evaporation of the Et₂O gave 295 mg of 12 which yielded 273 mg (83%) of the HCl salt, mp 254–256° dec, after a recrystallization from *i*-PrOH–Me₂CO: mass spectrum M⁺ 231 (base). Anal. (C₁₅H₂₁NO·HCl) C, H, N.

2,9 α -Dimethyl-2'-hydroxy-6,7-benzomorphan (14) Hydrobromide. A. From 9. Red phosphorus (60 mg, 1.94 mmol), 120 mg (0.485 mmol) of 9, 4 ml (23.5 mmol) of 50% HI, 8 ml of AcOH, and 2 ml of H₂O were refluxed for 6 hr, cooled, diluted with H₂O, and filtered. The filtrate was concentrated in vacuo, diluted with H₂O, made basic with NH₄OH, and extracted with CHCl₃–EtOH (3:1). Drying and evaporation of the extracts left 100 mg of a brown solid which was triturated in *i*-PrOH, filtered, and washed with Me₂CO to give 20 mg of 14, mp 217–219° dec. The filtrate was evaporated to dryness, and the residue was purified over SiO₂. Elution with CHCl₃–EtOH (9:1–8:2) gave an additional 28 mg of 14. Recrystallization of the combined crops from *i*-Pr₂O gave 38 mg (36%) of prisms, mp 225–227°. The hydrobromide (from EtOH–Et₂O) melted at 245–246°: NMR (CD₃OD, free base, 60 MHz) 0.89 (d, J = 7 Hz, 3, C-9, CH₃); δ 2.8, 9 mass spectrum M⁺ 217 (base). Anal. (C₁₄H₁₉NO·HBr) C, H, N.

B. From 12. Compound 12 (285 mg, 1.06 mmol) and 9 ml of 48% HBr were refluxed together for 1.5 hr and evaporated to dryness in vacuo. The gummy residue was treated with Me₂CO to give 273 mg (86.4%) of 14·HBr, mp 243–245° (from EtOH–Et₂O), identical with that described under A.

2,9 β -Dimethyl-2'-methoxy-6,7-benzomorphan (13) Oxalate. The oxalate (20 mg, 0.059 mmol) of 11 was hydrogenated (10 mg of 10% Pd/C, 5 ml of HOAc, and 4 drops of 60% HClO₄) for 4 days at 40° and 55 psi. After removal of catalyst and HOAc, the

residue, in H₂O, was made basic with 12 M NH₄OH and extracted with Et₂O. Drying and evaporation of the extracts gave 17 mg of oil which was converted to 11 mg (58%) of 13-oxalate, mp 196–197°, identical with authentic material.²

Interconversion of 9 and 10. Compound 10 (10 mg, 0.034 mmol) and the MeOH–NaOMe prepared from 2 mg (0.087 mmol) of Na and 0.2 ml of MeOH were stirred overnight at room temperature. Removal of MeOH in vacuo, solution of the residue in CHCl₃, and evaporation of the H₂O-washed, dried CHCl₃ solution gave 8 mg of 9, identical (TLC, ir) with that described above.

Ac₂O (10 drops), 8 mg (0.032 mmol) of 9, and 1 drop of C₅H₅N were stirred at room temperature for 1 day, poured into ice–H₂O, basified with K₂CO₃, and extracted with CHCl₃. The dried, evaporated (in vacuo below 20°) extract gave 10 mg of solid which was recrystallized from ligroine (bp 30–60°) yielding 6 mg of 9, mp 94–96°, identical with that described above.

Acknowledgment. We are indebted to Drs. Arthur Jacobson and Kenner Rice for valuable suggestions and to the Section on Instrumentation and Analytical Services for analytical and spectral data.

References and Notes

- (1) Visiting Associate from Tanabe Laboratories, Tokyo.
- (2) H. Inoue, T. Oh-ishi, and E. L. May, *J. Med. Chem.*, **18**, 787 (1975).
- (3) The α and β designations used in this paper are with respect to the hydroaromatic ring; see ref 9 for preferred Chemical Abstracts nomenclature.
- (4) H. Hodjat, A. Lattes, J. P. Laval, J. Moulines, and J. J. Perie, *J. Heterocycl. Chem.*, **9**, 1081 (1972), and pertinent references cited therein.
- (5) Fieser and Fieser, "Reagents for Organic Synthesis", Vol. I, Wiley, New York, N.Y., 1967, p 645; K. B. Wiberg and S. D. Nielsen, *J. Org. Chem.*, **29**, 3353 (1964).
- (6) D. P. Vaughan and A. H. Beckett, *J. Pharm. Pharmacol.*, **25**, 895 (1973).
- (7) The dihedral angle between C-1 H and C-8 H is about 90° in 9, 10, and 11.
- (8) S. E. Fullerton, E. L. May, and E. D. Becker, *J. Org. Chem.*, **27**, 2144 (1962).
- (9) T. Oh-ishi, A. E. Jacobson, R. S. Wilson, H. J. C. Yeh, and E. L. May, *J. Org. Chem.*, **39**, 1347 (1974).
- (10) T. D. Perrine, L. Atwell, I. B. Tice, A. E. Jacobson, and E. L. May, *J. Pharm. Sci.*, **61**, 86 (1972).
- (11) J. H. Ager, S. E. Fullerton, and E. L. May, *J. Med. Chem.*, **6**, 322 (1963).
- (12) E. L. May and M. Takeda, *J. Med. Chem.*, **13**, 805 (1970).
- (13) N. Yokoyama, F. B. Block, and F. H. Clarke, *J. Med. Chem.*, **13**, 488 (1970).
- (14) H. H. Swain and M. H. Seevers, private communication from the Department of Pharmacology, University of Michigan; Committee on Problems of Drug Dependence, National Academy of Sciences, Bulletin on Narcotics, Vol. XXV (no. 2), 1972, p 25.

Interferon Inducing Activities of Derivatives of 1,3-Dimethyl-4-(3-dimethylaminopropylamino)-1*H*-pyrazolo[3,4-*b*]quinoline and Related Compounds

R. R. Crenshaw,* George M. Luke, and Paul Siminoff


Research Division, Bristol Laboratories, Division of Bristol-Myers Company, Syracuse, New York 13201.

Received July 21, 1975

Syntheses and interferon inducing activities are reported for 137 relatives of 1,3-dimethyl-4-(3-dimethylaminopropylamino)-1*H*-pyrazolo[3,4-*b*]quinoline (1). Three different generalized synthetic schemes for the preparation of pyrazolo[3,4-*b*]quinolines are presented and limitations contrasted. Other heterocyclic nuclei containing the 3-dimethylaminopropylamino side chain include pyridine, quinoline, acridine, pyrazolo[3,4-*b*]pyridine, pyrazolo[3,4-*b*][1,8]naphthyridine, pyrazolo[4',3':5,6]pyrido[2,3-*d*]pyrimidine, dipyrazolo[3,4-*b*:4',3'-*e*]pyridine, pyrrolo[2,3-*b*]quinoline, isothiazolo[5,4-*b*]quinoline, and pyrido[2,3-*h*]pyrazolo[3,4-*b*]quinoline. Structural requirements for interferon induction in this series are discussed and two of the more active compounds (172 and 196) are compared directly with tilorone.

The capacity of an organism to produce interferon in response to infection by viruses or certain protozoan parasites is thought to be an important nonspecific defense mechanism. The interferon system is the earliest component of the host defense to become operative following virus infection and may also play a role in the later stages of recovery.¹ It is now well established that, once evoked, interferon will inhibit the replication of a wide variety of both RNA- and DNA-containing cytopathic and oncogenic viruses.² An agent which stimulates release and/or in vivo synthesis of interferon thus has implications for the development of a clinically useful broad-spectrum antiviral drug. Since the discovery of the interferon system in 1957,³ a number of polymeric substances have been reported which stimulate interferon production, but all of these have limitations in clinical utility.⁴ Impetus for the search for a monomeric low-molecular-weight inducer of interferon was provided by reports that 2,7-bis[2-(diethylamino)-ethoxy]fluoren-9-one (tilorone) and congeners induce interferon activity in mice.^{5,6} A preliminary report from our laboratories disclosed the interferon-eliciting activity of an entirely different structural type, viz. the pyrazo-

lo[3,4-*b*]quinoline 1 (BL-20803).⁷ We now report results



1

of a research program designed to (i) define structural features of 1 responsible for the interferon-eliciting activity and (ii) increase potency relative to 1 with a concomitant improvement in therapeutic ratio.

Chemistry. Relatives of 1 which were prepared for biological evaluation are listed in Tables III and IV. Some of the simpler fragment moieties of 1 and related acridines were prepared by literature procedures as indicated in Table III. The amide 65, which may be viewed as a hydrolytically cleaved form of 1, was prepared from the corresponding acid chloride and 3-dimethylaminopropylamine. Treatment of 65 with diborane in THF gave the reduced derivative 66.